Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 22, 2026, titled "Zydus launches the world s first biosimilar of Nivolumab, Tishtha , in India to treat multiple cancers".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has launched 'Tishtha', which it claims is the world's first biosimilar of the cancer immunotherapy drug Nivolumab, in India. The product is intended to treat multiple types of cancer. Nivolumab is an established blockbuster biologic, and a biosimilar version offers a more affordable alternative to expensive original therapy. Being the first such launch globally gives Zydus a first-mover position in this segment. India is one of the key emerging markets for affordable cancer treatments, making this a notable commercial milestone.
This launch strengthens Zydus's specialty and oncology portfolio and could open a new high-margin revenue stream. For shareholders, it signals innovation capability and growth potential in the biosimilars space, which may be viewed positively by the market.